LONITEN 10MG TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
19-11-2013
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MINOXIDIL
Fáanlegur frá:
PFIZER CANADA ULC
ATC númer:
C02DC01
INN (Alþjóðlegt nafn):
MINOXIDIL
Skammtar:
10MG
Lyfjaform:
TABLET
Samsetning:
MINOXIDIL 10MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
DIRECT VASODILATORS
Vörulýsing:
Active ingredient group (AIG) number: 0114429003; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
1998-05-04
Vara einkenni
_LONITEN (minoxidil tablets USP) Product Monograph _
_ Page 1 of 25 _
PRODUCT MONOGRAPH
PR
LONITEN
®
(Minoxidil Tablets USP)
2.5 mg and 10 mg
ANTIHYPERTENSIVE
®
TM Pharmacia & Upjohn Company LLC
Pfizer Canada Inc., Licensee
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
November 14, 2013
©
Pfizer Canada Inc. 2013
SUBMISSION CONTROL NO: 167423
_LONITEN (minoxidil tablets USP) Product Monograph _
_ Page 2 of 25 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
DETAILED PHARMACOLOGY
......................................
Lestu allt skjalið
